The present invention relates to the use of F4.sup.+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

The present invention relates to the use of F4.sup.+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

A method of neutralizing or mitigating a drug-induced mitochondrial dysfunction or impairment for an individual, the method including providing to the individual an effective amount of a composition containing glycine or a functional derivative thereof and N-acetylcysteine or a functional derivative thereof. The drug-induced mitochondrial dysfunction or impairment is from at least one drug consumed by the individual selected from the group consisting of an anticonvulsant; a psychotropic other than an antipsychotic drug; an analgesic/anti-inflammatory drug other than acetaminophen; an antibiotic; an anti-arrhythmic drug; a steroid; a beta-blocker; and an immunization.

A method of neutralizing or mitigating a drug-induced mitochondrial dysfunction or impairment for an individual, the method including providing to the individual an effective amount of a composition containing glycine or a functional derivative thereof and N-acetylcysteine or a functional derivative thereof. The drug-induced mitochondrial dysfunction or impairment is from at least one drug consumed by the individual selected from the group consisting of an anticonvulsant; a psychotropic other than an antipsychotic drug; an analgesic/anti-inflammatory drug other than acetaminophen; an antibiotic; an anti-arrhythmic drug; a steroid; a beta-blocker; and an immunization.

The present invention relates to the field of food supplement and medicament supporting muscle metabolism, more precisely muscle protein synthesis. In particular, the invention relates to a composition comprising N-carbamoylputrescine (NCP). The invention further relates to the non-therapeutic use of N-carbamoylputrescine (NCP) to enhance muscle protein synthesis in a subject. Moreover, the invention also relates to N-carbamoylputrescine for its use as a medicament.

The present invention relates to the field of food supplement and medicament supporting muscle metabolism, more precisely muscle protein synthesis. In particular, the invention relates to a composition comprising N-carbamoylputrescine (NCP). The invention further relates to the non-therapeutic use of N-carbamoylputrescine (NCP) to enhance muscle protein synthesis in a subject. Moreover, the invention also relates to N-carbamoylputrescine for its use as a medicament.

A method of using ZnO particles for the treatment of colon cancer and a method of using the particles for reducing the concentration of an organic contaminant in an aqueous solution is described. The ZnO particles are substantially spherical and may have nanopetals that provide a nanoflower morphology. The synthesis and characterization of the ZnO particles is also discussed.

A method of using ZnO particles for the treatment of colon cancer and a method of using the particles for reducing the concentration of an organic contaminant in an aqueous solution is described. The ZnO particles are substantially spherical and may have nanopetals that provide a nanoflower morphology. The synthesis and characterization of the ZnO particles is also discussed.

Disclosed herein are embodiments of compositions and combinations that can be used in combination with animal food. In some embodiments, the combinations comprise various compositions that can provide health benefits for animals, such as domestic or companion animals and/or feed animals. The combinations can be used to help maintain and/or promote animal health and well-being, and in some embodiments can help promote an increase in animal longevity.

Disclosed herein are embodiments of compositions and combinations that can be used in combination with animal food. In some embodiments, the combinations comprise various compositions that can provide health benefits for animals, such as domestic or companion animals and/or feed animals. The combinations can be used to help maintain and/or promote animal health and well-being, and in some embodiments can help promote an increase in animal longevity.